# A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

> **NCT04705350** · PHASE1 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 16 (actual)

## Conditions studied

- Healthy Study Participants

## Interventions

- **DRUG:** Zampilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04705350
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705350, "A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04705350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*